1. Home
  2. SNY
  3. SNY News

Latest Sanofi ADS (SNY) News on February 22, 2025

Press Release: ECCO 2025: new duvakitug data reinforce best-in-class potential in ulcerative colitis and Crohn’s disease
SNY

GlobeNewswire

9 hours ago

Press Release: ECCO 2025: new duvakitug data reinforce best-in-class potential in ulcerative colitis and Crohn’s disease

Teva and Sanofi Present New Positive Phase 2b Study Results at ECCO 2025 Reinforcing Best-in-Class Potential of Duvakitug (Anti-TL1A) in Ulcerative Colitis and Crohn’s Disease
SNY

GlobeNewswire

9 hours ago

Teva and Sanofi Present New Positive Phase 2b Study Results at ECCO 2025 Reinforcing Best-in-Class Potential of Duvakitug (Anti-TL1A) in Ulcerative Colitis and Crohn’s Disease

Pharma Stock Roundup: EU Nod to MRK's Welireg, IONS' Q4 Results & More
SNY

Zacks

a day ago

Pharma Stock Roundup: EU Nod to MRK's Welireg, IONS' Q4 Results & More

Sanofi moves closer to selling controlling stake in $17bn-valued Opella
SNY

Pharmaceutical Technology

3 days ago

Sanofi moves closer to selling controlling stake in $17bn-valued Opella

Sanofi reaches consumer health deal; Supernus antidepressant fails study
SNY

BioPharma Dive

3 days ago

Sanofi reaches consumer health deal; Supernus antidepressant fails study

Challenges mount for vaccine makers
SNY

Pharma Voice

3 days ago

Challenges mount for vaccine makers

Press Release: Sanofi and CD&R sign Opella share purchase agreement
SNY

GlobeNewswire

3 days ago

Press Release: Sanofi and CD&R sign Opella share purchase agreement

SNY and REGN's Dupixent sBLA for Skin Disease Gets FDA's Priority Tag
SNY

Zacks

4 days ago

SNY and REGN's Dupixent sBLA for Skin Disease Gets FDA's Priority Tag

FDA to review Sanofi and Regeneron’s Dupixent sBLA for bullous pemphigoid
SNY

Pharmaceutical Technology

4 days ago

FDA to review Sanofi and Regeneron’s Dupixent sBLA for bullous pemphigoid

Press Release: Dupixent sBLA accepted for FDA priority review for the targeted treatment of bullous pemphigoid
SNY

GlobeNewswire

4 days ago

Press Release: Dupixent sBLA accepted for FDA priority review for the targeted treatment of bullous pemphigoid

Pharma Stock Roundup: NVS, ABBV M&A Deals, FDA Nod to RHHBY, PFE Drugs
SNY

Zacks

8 days ago

Pharma Stock Roundup: NVS, ABBV M&A Deals, FDA Nod to RHHBY, PFE Drugs

Banks on the Hook for Sanofi Buyout Face Agonizing Wait to Sell
SNY

Bloomberg

8 days ago

Banks on the Hook for Sanofi Buyout Face Agonizing Wait to Sell

SNY

Morningstar Research

9 days ago

Analyst Report: Sanofi

Press Release: Filing of the 2024 U.S. Form 20-F and French “Document d’Enregistrement Universel” containing the Annual Financial Report
SNY

GlobeNewswire

9 days ago

Press Release: Filing of the 2024 U.S. Form 20-F and French “Document d’Enregistrement Universel” containing the Annual Financial Report

J&J stops Phase III trial of Sanofi’s E. Coli vaccine citing ‘disappointing’ results
SNY

Clinical Trials Arena

9 days ago

J&J stops Phase III trial of Sanofi’s E. Coli vaccine citing ‘disappointing’ results

Sanofi/Johnson & Johnson Partnered Vaccine Against Bacterial Sepsis Flunks Late-Stage Study
SNY

Benzinga

9 days ago

Sanofi/Johnson & Johnson Partnered Vaccine Against Bacterial Sepsis Flunks Late-Stage Study

Sanofi to take $250M charge on study failure for E. coli vaccine
SNY

BioPharma Dive

9 days ago

Sanofi to take $250M charge on study failure for E. coli vaccine

Press Release: Update on extraintestinal pathogenic E. coli vaccine phase 3 clinical study
SNY

GlobeNewswire

9 days ago

Press Release: Update on extraintestinal pathogenic E. coli vaccine phase 3 clinical study

Sanofi (SNY): Among the Best International Dividend Stocks to Buy Now
SNY

Insider Monkey

10 days ago

Sanofi (SNY): Among the Best International Dividend Stocks to Buy Now

SNY

Argus Research

11 days ago

Daily Spotlight: A Range of Sovereign Debt Yields

SNY

Argus Research

12 days ago

Weekly Stock List

Sanofi increases ownership stake partaking in pharma buyback trend
SNY

Pharmaceutical Technology

15 days ago

Sanofi increases ownership stake partaking in pharma buyback trend

Novo Nordisk’s haemophilia A drug stops bleeds in 74% of children
SNY

Clinical Trials Arena

15 days ago

Novo Nordisk’s haemophilia A drug stops bleeds in 74% of children

Press Release: Execution of a share buyback agreement for up to €2 billion
SNY

GlobeNewswire

15 days ago

Press Release: Execution of a share buyback agreement for up to €2 billion

Sanofi (SNY): Among the Best Foreign Dividend Stocks to Invest In Now
SNY

Insider Monkey

17 days ago

Sanofi (SNY): Among the Best Foreign Dividend Stocks to Invest In Now

SNY

Thomson Reuters StreetEvents

17 days ago

Q4 2024 Regeneron Pharmaceuticals Inc Earnings Call

Regeneron Pharmaceuticals Beats On Libtayo's Back, Unveils Dividend
SNY

Investor's Business Daily

18 days ago

Regeneron Pharmaceuticals Beats On Libtayo's Back, Unveils Dividend

Regeneron Beats on Q4 Earnings, Initiates Quarterly Dividend
SNY

Zacks

18 days ago

Regeneron Beats on Q4 Earnings, Initiates Quarterly Dividend

MRK Gets Positive CHMP Nod for 21-Valent Pneumococcal Jab Capvaxive
SNY

Zacks

19 days ago

MRK Gets Positive CHMP Nod for 21-Valent Pneumococcal Jab Capvaxive

Sanofi kicks off share buyback plan with $3bn L’Oréal stake purchase
SNY

Pharmaceutical Technology

19 days ago

Sanofi kicks off share buyback plan with $3bn L’Oréal stake purchase

SNY

Argus Research

19 days ago

Analyst Report: Sanofi SA

SNY

Argus Research

19 days ago

Market Digest: SNY, BX, CLS, FL, GE, MSFT, NFG, SHEL, SYK, WBA, WM, WY, ABBV, BKR

Sanofi’s Sarclisa combo approved in China for multiple myeloma
SNY

Pharmaceutical Technology

19 days ago

Sanofi’s Sarclisa combo approved in China for multiple myeloma

SNY

MT Newswires

19 days ago

Sanofi to Buyback $3 Billion in Shares From L'Oreal

L’Oreal Sells €3 Billion of Sanofi Stock Back to Drugmaker
SNY

Bloomberg

19 days ago

L’Oreal Sells €3 Billion of Sanofi Stock Back to Drugmaker

Sanofi Buys Back Shares From L’Oréal for 3 Billion Euros
SNY

WWD

19 days ago

Sanofi Buys Back Shares From L’Oréal for 3 Billion Euros

Press Release: Sanofi announces buy back of shares from L’Oréal
SNY

GlobeNewswire

19 days ago

Press Release: Sanofi announces buy back of shares from L’Oréal

Sanofi reports Q4 2024 increase in net income to $916m
SNY

Pharmaceutical Technology

22 days ago

Sanofi reports Q4 2024 increase in net income to $916m

Pharma Stock Roundup: SNY and RHHBY's Q4 Earnings & More
SNY

Zacks

22 days ago

Pharma Stock Roundup: SNY and RHHBY's Q4 Earnings & More

Novartis sets ‘ambitious’ target; Skyrizi, Rinvoq sales climb
SNY

BioPharma Dive

22 days ago

Novartis sets ‘ambitious’ target; Skyrizi, Rinvoq sales climb

Sanofi SA (SNY) Q4 2024 Earnings Call Highlights: Strong Sales Growth and Strategic Investments ...
SNY

GuruFocus.com

22 days ago

Sanofi SA (SNY) Q4 2024 Earnings Call Highlights: Strong Sales Growth and Strategic Investments ...

Press Release: Sarclisa is the first anti-CD38 treatment approved in China for patients with newly diagnosed multiple myeloma ineligible for transplant
SNY

GlobeNewswire

22 days ago

Press Release: Sarclisa is the first anti-CD38 treatment approved in China for patients with newly diagnosed multiple myeloma ineligible for transplant

SNY

Morningstar Research

23 days ago

Analyst Report: Sanofi

Sanofi (SNY) Q4 2024 Earnings Call Transcript
SNY

Motley Fool

23 days ago

Sanofi (SNY) Q4 2024 Earnings Call Transcript

SNY

MT Newswires

23 days ago

Sector Update: Health Care Stocks Rise Pre-Bell Thursday

SNY

MT Newswires

23 days ago

Sector Update: Health Care

Sanofi Misses on Q4 Earnings & Sales, Expects Higher Profits in 2025
SNY

Zacks

23 days ago

Sanofi Misses on Q4 Earnings & Sales, Expects Higher Profits in 2025

SNY

Associated Press Finance

23 days ago

Sanofi: Q4 Earnings Snapshot

SNY

Argus Research

24 days ago

The Argus Min Vol Model Portfolio

Four Years After Covid-19 Success, mRNA Vaccines Aren’t Ready for Bird Flu
SNY

Barrons.com

a month ago

Four Years After Covid-19 Success, mRNA Vaccines Aren’t Ready for Bird Flu

Pharma Stock Roundup: JNJ's Q4 Earnings, FDA Nod to AZN, Daiichi Drug
SNY

Zacks

a month ago

Pharma Stock Roundup: JNJ's Q4 Earnings, FDA Nod to AZN, Daiichi Drug

SNY's Sarclisa Gets EU Nod for Expanded Use in Multiple Myeloma
SNY

Zacks

a month ago

SNY's Sarclisa Gets EU Nod for Expanded Use in Multiple Myeloma

FDA lifts hold on Opella’s trial to support switch of Cialis to OTC drug
SNY

Clinical Trials Arena

a month ago

FDA lifts hold on Opella’s trial to support switch of Cialis to OTC drug

Press Release: Sarclisa approved in the EU as the first anti-CD38 therapy in combination with standard-of-care VRd to treat transplant-ineligible newly diagnosed multiple myeloma
SNY

GlobeNewswire

a month ago

Press Release: Sarclisa approved in the EU as the first anti-CD38 therapy in combination with standard-of-care VRd to treat transplant-ineligible newly diagnosed multiple myeloma

Denali Gains 26.6% in a Year: How Should You Play the Stock?
SNY

Zacks

a month ago

Denali Gains 26.6% in a Year: How Should You Play the Stock?

Press Release: Opella reaches study milestone for Cialis
SNY

GlobeNewswire

a month ago

Press Release: Opella reaches study milestone for Cialis

SK bioscience and Sanofi’s GBP410 vaccine enters global Phase III trials
SNY

Clinical Trials Arena

a month ago

SK bioscience and Sanofi’s GBP410 vaccine enters global Phase III trials

Sanofi to increase competition in atopic dermatitis market after Dupixent success
SNY

Clinical Trials Arena

a month ago

Sanofi to increase competition in atopic dermatitis market after Dupixent success

Sanofi: Information concerning the total number of voting rights and shares – November 2024
SNY

GlobeNewswire

a month ago

Sanofi: Information concerning the total number of voting rights and shares – November 2024

SNY's Subcutaneous Sarclisa Proves Non-Inferior to IV Formulation (Revised)
SNY

Zacks

a month ago

SNY's Subcutaneous Sarclisa Proves Non-Inferior to IV Formulation (Revised)

Press Release: Sarclisa obtains first approval in China for the treatment of adult patients with relapsed or refractory multiple myeloma
SNY

GlobeNewswire

a month ago

Press Release: Sarclisa obtains first approval in China for the treatment of adult patients with relapsed or refractory multiple myeloma

IGM Biosciences downgraded to Hold from Buy at Jefferies
SNY

TipRanks

a month ago

IGM Biosciences downgraded to Hold from Buy at Jefferies

SNY's Subcutaneous Sarclisa Outperforms IV Formulation in Cancer Study
SNY

Zacks

a month ago

SNY's Subcutaneous Sarclisa Outperforms IV Formulation in Cancer Study

Sanofi reports positive results from trial of multiple myeloma drug candidate
SNY

Clinical Trials Arena

a month ago

Sanofi reports positive results from trial of multiple myeloma drug candidate

Sanofi's Blood Cancer Drug's New Subcutaneous Formulation Hits Primary Goal In Late-Stage In Multiple Myeloma
SNY

Benzinga

a month ago

Sanofi's Blood Cancer Drug's New Subcutaneous Formulation Hits Primary Goal In Late-Stage In Multiple Myeloma

Press Release: New Sarclisa subcutaneous formulation met co-primary endpoints in the IRAKLIA phase 3 study in multiple myeloma
SNY

GlobeNewswire

a month ago

Press Release: New Sarclisa subcutaneous formulation met co-primary endpoints in the IRAKLIA phase 3 study in multiple myeloma

Sanofi taps Alloy Therapeutics for CNS antisense drug development
SNY

Pharmaceutical Technology

a month ago

Sanofi taps Alloy Therapeutics for CNS antisense drug development

Third Rock-backed Maze Therapeutics reveals profit in US IPO filing
SNY

Reuters

a month ago

Third Rock-backed Maze Therapeutics reveals profit in US IPO filing

Denali's ALS Study Fails to Meet Primary and Secondary Endpoints
SNY

Zacks

a month ago

Denali's ALS Study Fails to Meet Primary and Secondary Endpoints

Sanofi Down 10% in 3 Months: How Should You Play the Stock?
SNY

Zacks

a month ago

Sanofi Down 10% in 3 Months: How Should You Play the Stock?

Drugmakers to raise US prices on over 250 medicines starting Jan. 1
SNY

Reuters

2 months ago

Drugmakers to raise US prices on over 250 medicines starting Jan. 1

Olympian Jordan Chiles is setting her sights on a new goal: raising awareness of type 1 diabetes
SNY

Fortune

2 months ago

Olympian Jordan Chiles is setting her sights on a new goal: raising awareness of type 1 diabetes

The Zacks Analyst Blog Highlights ServiceNow, AMD, Sanofi, Team and United-Guardian
SNY

Zacks

2 months ago

The Zacks Analyst Blog Highlights ServiceNow, AMD, Sanofi, Team and United-Guardian

Top Research Reports for ServiceNow, AMD & Sanofi
SNY

Zacks

2 months ago

Top Research Reports for ServiceNow, AMD & Sanofi

Why Is Sanofi (SNY) Among the Best European Dividend Stocks To Buy Now?
SNY

Insider Monkey

2 months ago

Why Is Sanofi (SNY) Among the Best European Dividend Stocks To Buy Now?

Sanofi's 21-Valent Pneumococcal Vaccine Enters Phase III
SNY

Zacks

2 months ago

Sanofi's 21-Valent Pneumococcal Vaccine Enters Phase III

SK bioscience and Sanofi expand agreement for pneumococcal conjugate vaccines
SNY

Pharmaceutical Technology

2 months ago

SK bioscience and Sanofi expand agreement for pneumococcal conjugate vaccines

Press Release: Sanofi initiates phase 3 program for PCV21 and expands collaboration with SK bioscience for next-generation pneumococcal conjugate vaccines
SNY

GlobeNewswire

2 months ago

Press Release: Sanofi initiates phase 3 program for PCV21 and expands collaboration with SK bioscience for next-generation pneumococcal conjugate vaccines

Sanofi’s Tolebrutinib Receives FDA Breakthrough Therapy Designation for nrSPMS
SNY

TipRanks

2 months ago

Sanofi’s Tolebrutinib Receives FDA Breakthrough Therapy Designation for nrSPMS

Why Cytokinetics Stock Was a Nearly 5% Winner Today
SNY

Motley Fool

2 months ago

Why Cytokinetics Stock Was a Nearly 5% Winner Today

Pharma Stock Roundup: PFE's 2025 Outlook, MRK & ABBV's M&A Deals
SNY

Zacks

2 months ago

Pharma Stock Roundup: PFE's 2025 Outlook, MRK & ABBV's M&A Deals

SNY

MT Newswires

2 months ago

Cytokinetics Says Sanofi Acquiring Rights for Aficamten in Greater China

Presse release: Jean-Paul Kress to join Sanofi's Board of Directors
SNY

GlobeNewswire

2 months ago

Presse release: Jean-Paul Kress to join Sanofi's Board of Directors

SNY, TEVA Stocks Jump on Encouraging Data From IBD Drug Study
SNY

Zacks

2 months ago

SNY, TEVA Stocks Jump on Encouraging Data From IBD Drug Study

Strength Seen in Sanofi (SNY): Can Its 6.7% Jump Turn into More Strength?
SNY

Zacks

2 months ago

Strength Seen in Sanofi (SNY): Can Its 6.7% Jump Turn into More Strength?

Sanofi and Teva’s duvakitug meets primary endpoints in Phase IIb trial
SNY

Clinical Trials Arena

2 months ago

Sanofi and Teva’s duvakitug meets primary endpoints in Phase IIb trial

SNY

Morningstar Research

2 months ago

Analyst Report: Sanofi

Teva and Sanofi jump on experimental bowel disease drug success
SNY

Yahoo Finance Video

2 months ago

Teva and Sanofi jump on experimental bowel disease drug success

Teva Catapults 26%, Hitting A Six-Year High, After Scoring A Win With Sanofi-Tied Drug
SNY

Investor's Business Daily

2 months ago

Teva Catapults 26%, Hitting A Six-Year High, After Scoring A Win With Sanofi-Tied Drug

Teva, Sanofi Say Inflammatory Bowel Disease Drug Study Meets Primary Endpoints
SNY

MT Newswires

2 months ago

Teva, Sanofi Say Inflammatory Bowel Disease Drug Study Meets Primary Endpoints

Positive Test Results Reported for Teva-Sanofi Drug for Ulcerative Colitis, Crohn's
SNY

Investopedia

2 months ago

Positive Test Results Reported for Teva-Sanofi Drug for Ulcerative Colitis, Crohn's

SNY

MT Newswires

2 months ago

Update: Teva, Sanofi Shares Jump as Phase 2B Duvakitug Study Meets Primary Endpoints in Inflammatory Bowel Disease

Teva Stock Soars 19% as Game-Changing IBD Drug Duvakitug Crushes Trial Expectations
SNY

GuruFocus.com

2 months ago

Teva Stock Soars 19% as Game-Changing IBD Drug Duvakitug Crushes Trial Expectations

Teva, Cloudflare, Sanofi: Trending Tickers
SNY

Yahoo Finance Video

2 months ago

Teva, Cloudflare, Sanofi: Trending Tickers

Teva Soars, Sanofi Gains on Strong Trial Results for IBD Treatment
SNY

The Wall Street Journal

2 months ago

Teva Soars, Sanofi Gains on Strong Trial Results for IBD Treatment

Teva Catapults 20%, Nearing A Five-Year High, After Scoring A Win With Sanofi-Tied Drug
SNY

Investor's Business Daily

2 months ago

Teva Catapults 20%, Nearing A Five-Year High, After Scoring A Win With Sanofi-Tied Drug

Teva Shares Soar on Early Bowel Disease Drug Data
SNY

Barrons.com

2 months ago

Teva Shares Soar on Early Bowel Disease Drug Data

Why Are Teva And Sanofi Stocks Trading Higher On Tuesday?
SNY

Benzinga

2 months ago

Why Are Teva And Sanofi Stocks Trading Higher On Tuesday?

SNY

MT Newswires

2 months ago

Teva, Sanofi Say Phase 2B Duvakitug Study Meets Primary Endpoints in Inflammatory Bowel Disease

Press Release: Duvakitug positive phase 2b results demonstrate best-in-class potential in ulcerative colitis and Crohn’s disease
SNY

GlobeNewswire

2 months ago

Press Release: Duvakitug positive phase 2b results demonstrate best-in-class potential in ulcerative colitis and Crohn’s disease

Share on Social Networks: